Equity Derivatives of Point72 Associates, LLC in Alterity Therapeutics Limited We refer to Guidance Note 20: Equity Derivatives (GN20) issued by the Australian Takeovers Panel. Terms not defined in this notice have the meaning given to them in GN20. GN20 relevantly provides that the non-disclosure of long positions, including long equity derivative positions, may give rise to unacceptable circumstances. Point72 Asset Management, L.P. (Point72), as investment manager of Point72 Associates, LLC (the Fund), discloses the below information on behalf of the Fund, as at the date of this letter, under GN20. Point72 consents to Alterity Therapeutics Limited releasing the information contained in this formal disclosure to the ASX. Please provide confirmation to us once this has been released to the ASX.
Total number of securities to which derivatives relate as 3 February 2025§ 187,910,474 ORDs; and§ 135,120 ADRs (which, when converted, represents 81,072,000 ORDs)
ATH Price at posting:
1.2¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)